H. Hatakeyama

发表

siRNA delivery by multifunctional envelope-type nano device (MEND)

H. Harashima, H. Akita, H. Hatakeyama, 2010 .

Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid

H Akita, H Hatakeyama, H Harashima, 2007, Gene Therapy.

A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.

Shiroh Futaki, Yukio Nagasaki, Hideyoshi Harashima, 2009, Journal of controlled release : official journal of the Controlled Release Society.

Investigation of Metabolomic Changes in Sunitinib-Resistant Human Renal Carcinoma 786-O Cells by Capillary Electrophoresis-Time of Flight Mass Spectrometry.

H. Hatakeyama, A. Hisaka, Hiromi Sato, 2018, Biological & pharmaceutical bulletin.

Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.

S. Futaki, H. Harashima, Yusuke Sato, 2011, Biomaterials.

Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.

H. Harashima, H. Akita, H. Hatakeyama, 2007, International journal of pharmaceutics.

In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus.

Y. Hirata, M. Kohara, H. Harashima, 2014, Scientific Reports.

Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake.

Hideyoshi Harashima, Hiroto Hatakeyama, H. Harashima, 2010, International journal of pharmaceutics.

Effects on Metabolism in Astrocytes Caused by cGAMP, Which Imitates the Initial Stage of Brain Metastasis

Hiroki Tanaka, H. Akita, H. Hatakeyama, 2021, International journal of molecular sciences.

A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.

H. Harashima, Yusuke Sato, H. Akita, 2012, Journal of controlled release : official journal of the Controlled Release Society.

Recent Advances in Endogenous and Exogenous Stimuli-Responsive Nanocarriers for Drug Delivery and Therapeutics.

H. Hatakeyama, 2017, Chemical & pharmaceutical bulletin.

Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.

G. Kibria, H. Harashima, H. Hatakeyama, 2011, Journal of controlled release : official journal of the Controlled Release Society.

Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium.

Takahiro Nomoto, Y. Matsumoto, K. Kataoka, 2013, ACS nano.

Determinants of Intestinal Availability for P-glycoprotein Substrate Drugs Estimated by Extensive Simulation With Mathematical Absorption Models.

H. Hatakeyama, Hiroshi Suzuki, A. Hisaka, 2017, Journal of pharmaceutical sciences.

An apolipoprotein E modified liposomal nanoparticle: ligand dependent efficiency as a siRNA delivery carrier for mouse-derived brain endothelial cells.

H. Harashima, Yusuke Sato, H. Akita, 2014, International journal of pharmaceutics.

Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)

A. Sood, S. Ma, C. Ivan, 2018, Oncogene.

Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system.

S. Futaki, Y. Nagasaki, H. Harashima, 2009, Biological & pharmaceutical bulletin.

Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer

A. Sood, Wei Hu, H. Hatakeyama, 2016, Molecular Cancer Therapeutics.

Investigation of energy metabolic dynamism in hyperthermia-resistant ovarian and uterine cancer cells under heat stress

H. Hatakeyama, A. Hisaka, Kousei Ito, 2021, Scientific Reports.

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models

H. Hatakeyama, T. Uehara, Y. Arano, 2020, Journal for ImmunoTherapy of Cancer.

Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.

K. Chayama, Y. Hirata, M. Kohara, 2016, Journal of hepatology.

Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell‐specific liposomal siRNA delivery system

M. Morimoto, Takashi Nakamura, H. Harashima, 2022, Cancer science.

The effect of liposomal size on the targeted delivery of doxorubicin to Integrin alpha v beta 3-expressing tumor endothelial cells

G. Kibria, H. Harashima, H. Hatakeyama, 2019 .

The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.

G. Kibria, H. Harashima, H. Hatakeyama, 2013, Biomaterials.

A Neutral Envelope‐Type Nanoparticle Containing pH‐Responsive and SS‐Cleavable Lipid‐Like Material as a Carrier for Plasmid DNA

H. Harashima, Hiroki Tanaka, Yusuke Sato, 2013, Advanced healthcare materials.

A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response.

N. Kaji, Y. Baba, H. Harashima, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Inhibitory effects of ceramide kinase on Rac1 activation, lamellipodium formation, cell migration, and metastasis of A549 lung cancer cells.

K. Yamagata, H. Hatakeyama, Satoshi Tomizawa, 2020, Biochimica et biophysica acta. Molecular and cell biology of lipids.

Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect.

K. Osada, H. Akita, H. Hatakeyama, 2022, Journal of controlled release : official journal of the Controlled Release Society.

Induction of antitumor immunity in mice by the combination of nanoparticle-based Photothermolysis and anti-PD-1 checkpoint inhibition.

A. Sood, D. Piwnica-Worms, H. Hatakeyama, 2020, Nanomedicine : nanotechnology, biology, and medicine.

Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.

H. Harashima, H. Akita, H. Hatakeyama, 2014, Molecular pharmaceutics.

Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system

G. Kibria, H. Harashima, H. Hatakeyama, 2013, Archives of Pharmacal Research.

The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice.

N. Minakawa, A. Matsuda, H. Harashima, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor

H. Akita, H. Hatakeyama, A. Hisaka, 2022, Journal for ImmunoTherapy of Cancer.

Advances in an active and passive targeting to tumor and adipose tissues

Yu Sakurai, Hideyoshi Harashima, Hiroto Hatakeyama, 2015, Expert opinion on drug delivery.

Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors

H. Akita, H. Hatakeyama, Y. Sakurai, 2020, Cancers.

Combined nano cancer immunotherapy based on immune status in a tumor microenvironment.

Takashi Nakamura, H. Harashima, Yusuke Sato, 2022, Journal of controlled release : official journal of the Controlled Release Society.

Synthesis, structure, and biological activity of dumbbell-shaped nanocircular RNAs for RNA interference.

M. Maeda, S. Tsuneda, Yoshihiro Ito, 2011, Bioconjugate chemistry.

A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells.

Hideyoshi Harashima, Hiroto Hatakeyama, Takashi Nakamura, 2016, Journal of controlled release : official journal of the Controlled Release Society.

The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice.

N. Minakawa, A. Matsuda, H. Harashima, 2014, Journal of controlled release : official journal of the Controlled Release Society.

In vitro optimization of 2′-OMe-4′-thioribonucleoside–modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle

N. Minakawa, A. Matsuda, H. Harashima, 2013, Nucleic acids research.

2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

Prahlad T. Ram, K. Baggerly, J. H. Kim, 2014, Nature Communications.

A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma.

Hideyoshi Harashima, Hidetaka Akita, Hiroto Hatakeyama, 2011, Advanced drug delivery reviews.

HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer

M. Torres-Lugo, A. Sood, C. Rinaldi, 2017, Molecular Cancer Therapeutics.

Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system.

H. Harashima, Yusuke Sato, H. Akita, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer

Min Zhang, Prahlad T. Ram, Keith A. Baggerly, 2016, Nature Communications.

Intracellular stability of 2′-OMe-4′-thioribonucleoside modified siRNA leads to long-term RNAi effect

N. Minakawa, A. Matsuda, H. Harashima, 2012, Nucleic acids research.

Delivery of Nucleic Acids and Gene Delivery

I. Khalil, H. Harashima, H. Akita, 2011 .

A Multifunctional Envelope-Type Nano Device for Cancer Therapy

Hideyoshi Harashima, Ikramy A. Khalil, Hiroto Hatakeyama, 2019, Cancer Drug Delivery Systems Based on the Tumor Microenvironment.

An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.

H. Harashima, H. Hatakeyama, M. Hyodo, 2014, Biomaterials.

Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.

G. Kibria, H. Harashima, Yusuke Sato, 2016, International journal of pharmaceutics.

Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system

G. Kibria, H. Harashima, H. Hatakeyama, 2013, Archives of Pharmacal Research.

The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors.

H. Harashima, H. Akita, H. Hatakeyama, 2013, Biological & pharmaceutical bulletin.

Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity

H. Hatakeyama, K. Ueno, A. Hisaka, 2019, European journal of pharmacology.

A novel nonviral gene delivery system: multifunctional envelope-type nano device.

K. Kogure, H. Harashima, H. Akita, 2010, Advances in biochemical engineering/biotechnology.

Global Comparison of Changes in the Number of Test-Positive Cases and Deaths by Coronavirus Infection (COVID-19) in the World

N. Anzai, H. Hatakeyama, A. Hisaka, 2020, Journal of clinical medicine.

Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.

H. Hatakeyama, A. Hisaka, Hiromi Sato, 2018, Blood advances.

Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier.

H. Harashima, Yusuke Sato, H. Akita, 2015, International journal of pharmaceutics.

Reactivation of Anticancer Immunity by Resetting Interorgan Crosstalk in Immune-Suppressive Cells with a Nanoparticulated Anti-Inflammatory Drug.

Hiroki Tanaka, H. Akita, H. Hatakeyama, 2023, Small.

Instructions for use Title Hepatic Monoacylglycerol O-acyltransferase 1 as a PromisingTherapeutic Target for Steatosis , Obesity , and Type 2 Diabetes

N. Kaji, Y. Baba, H. Harashima, 2017 .

Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes

N. Kaji, Y. Baba, H. Harashima, 2014, Molecular therapy. Nucleic acids.

Molecular Tuning of a Vitamin E-Scaffold pH-Sensitive and Reductive Cleavable Lipid-like Material for Accelerated in Vivo Hepatic siRNA Delivery.

H. Harashima, Yusuke Sato, H. Akita, 2015, ACS biomaterials science & engineering.

Instructions for use Title Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain

H. Harashima, Yusuke Sato, H. Akita, 2017 .

Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.

G. Kibria, H. Harashima, H. Hatakeyama, 2012, Journal of controlled release : official journal of the Controlled Release Society.

A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma.

H. Harashima, H. Akita, H. Hatakeyama, 2015, Journal of controlled release : official journal of the Controlled Release Society.

Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo.

T. Suhara, H. Harashima, H. Akita, 2004, International journal of pharmaceutics.

Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp.

G. Kibria, H. Harashima, H. Hatakeyama, 2014, Biological & pharmaceutical bulletin.

Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid.

Noritada Kaji, Yoshinobu Baba, Radostin Danev, 2011, Biomaterials.

A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system.

G. Kibria, H. Harashima, H. Hatakeyama, 2011, International journal of pharmaceutics.

Relationship Between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells.

H. Harashima, Yusuke Sato, H. Hatakeyama, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.

H. Harashima, Yusuke Sato, H. Akita, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.

A. Sood, G. Lopez-Berestein, H. Hatakeyama, 2016, Methods in molecular biology.

Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.

Anil K. Shukla, M. Torres-Lugo, Ju-Seog Lee, 2016, Cell Reports.

A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications.

T Nakamura, H Akita, Y Yamada, 2012, Accounts of chemical research.

Delivering mRNA to Secondary Lymphoid Tissues by Phosphatidylserine‐Loaded Lipid Nanoparticles

Hiroki Tanaka, H. Akita, H. Hatakeyama, 2022, Advanced healthcare materials.

An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.

H. Harashima, H. Hatakeyama, M. Hyodo, 2014, Biomaterials.

Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)

A. Sood, C. Ivan, Shuhong Wu, 2018, Oncogene.

Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake.

H. Harashima, H. Hatakeyama, K. Hida, 2010, International journal of pharmaceutics.

Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid.

N. Kaji, Y. Baba, K. Nagayama, 2011, Biomaterials.

Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.

G. Kibria, H. Harashima, H. Hatakeyama, 2011, Journal of controlled release : official journal of the Controlled Release Society.

Investigation of Metabolomic Changes in Sunitinib-Resistant Human Renal Carcinoma 786-O Cells by Capillary Electrophoresis-Time of Flight Mass Spectrometry.

H. Hatakeyama, A. Hisaka, Hiromi Sato, 2018, Biological & pharmaceutical bulletin.

Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.

Anil K. Shukla, M. Torres-Lugo, Ju-Seog Lee, 2016, Cell reports.

A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system.

G. Kibria, H. Harashima, H. Hatakeyama, 2011, International journal of pharmaceutics.

The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles

E. Yonemochi, Hiroki Tanaka, H. Akita, 2024, Pharmaceutics.

[Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid].

K. Kogure, H. Harashima, H. Akita, 2007, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

Development of a Novel Systemic Gene Delivery System for Cancer Therapy with a Tumor‐Specific Cleavable PEG‐Lipid

K. Kogure, H. Harashima, H. Akita, 2008 .

Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System.

H. Harashima, H. Akita, H. Hatakeyama, 2015, Bioconjugate chemistry.

Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain

Yusuke Sato, H. Akita, H. Hatakeyama, 2014, International journal of nanomedicine.